Compare Campbell Soup Co. (CPB) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Eli Lilly And Co — how do they compare? Campbell Soup Co. trades at $19.38 (market cap $5.64B), while Eli Lilly And Co trades at $1,162.56 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 187.9× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (5.29%). Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Eli Lilly And Co for 93 Days on average.
| CPB | LLY | |
|---|---|---|
Market Cap | $5.64B | $1.06T |
Volume | 8,200,811 | 2,297,239 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $1.28K |
52-Week Low | $18.90 | $799.57 |
Typical Hold Time | 98 Days | 93 Days |
Enterprise Value | $12.70B | $1.11T |
Dividend Yield | 5.29% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $19.37, up 1.95% on the day, with a bearish technical outlook and mixed fundamentals. Recent Q4 2026 earnings missed expectations, while the company implemented a 36% dividend cut and announced a $500 million cost-savings plan. Valuation metrics appear reasonable with P/E of 14.44 and P/S of 0.58, but profit margins have declined from 9.16% in 2023 to 4.13% projected for 2026.
The outlook remains challenging with declining profitability and bearish analyst sentiment, though current valuation may offer value for patient investors. Key risks include ongoing margin pressure, competitive threats, and execution of the turnaround plan. With only 6.9% of analysts rating it Buy, the stock faces significant headwinds despite trading near consensus price target of $19.67.
Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.
Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
